Last reviewed · How we verify
NCT06944418
The Study of Differences in Eosinophil Function and Subsets in Patients With Eosinophilic Pulmonary Diseases
trial testing observation in Eosinophil Subtype in 300 participants. Currently enrolling.
1 January 2026
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 January 2024 |
| Primary completion | 1 January 2026 |
| Estimated completion | 1 January 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- observation
Conditions studied
- Eosinophil Subtype — all drugs for Eosinophil Subtype →
- Eosinophilic Pulmonary Diseases — all drugs for Eosinophilic Pulmonary Diseases →
Sponsor
Peking Union Medical College Hospital
Who can join
Adults 18 to 90, any sex, with Eosinophil Subtype or Eosinophilic Pulmonary Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study subjects of this research are patients with eosinophil-associated pulmonary diseases, including eosinophilic granulomatosis with polyangiitis, idiopathic hypereosinophilic syndrome, idiopathic acute eosinophilic pneumonia, idiopathic chronic eosinophilic pneumonia, and primary simple pulmonary eosinophilia. The aim is to detect eosinophil subtypes in peripheral blood based on surface protein expression, to understand the differences in eosinophil subtypes among patients with different diseases, to elucidate the significance of different eosinophil subtypes, and ultimately to provide a theoretical basis for the selection of treatment directions for patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06944418
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of observation
Trials testing the same drug.
- NCT06493448 — Prospective Observational Cohort Study · not yet recruiting
- NCT06432153 — Tampa Scale of Kinesiophobia for Heart Taiwan Version Validation · not yet recruiting
- NCT06491966 — Clinical Outcomes and Inflammatory Responses in Viral vs. Bacterial Sepsis · recruiting
- NCT06327165 — Predictability of ANI (Analgesia Nociception Index) for Spinal Hypotension · unknown
- NCT06114446 — The Evaluation of the Effectiveness of Nursing Care Education Provided With Immersive Virtual Reality · NA · completed
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06944418 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 25 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06944418.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing